Reported Earlier, ImmuCell Preliminary Q4 Sales Of $7.8M (+52% YoY) and Fiscal 2024 Of $26.5M (+52% YoY), Driven by Increased Production
Benzinga Newsdesk 1 year ago
News
Preliminary, Unaudited Total Sales Results: 20242023$ Increase% Increase During the Three-Month Periods Ended December 31,$7.8 million$5.1 million$2.7 million52%During the Years Ended December 31,$26.5
| Preliminary, Unaudited Total Sales Results: | ||||
| 2024 | 2023 | $ Increase | % Increase | |
| During the Three-Month Periods Ended December 31, | $7.8 million | $5.1 million | $2.7 million | 52% |
| During the Years Ended December 31, | $26.5 million | $17.5 million | $9.0 million | 52% |
During the three-month period ended December 31, 2024, annualized production output was approximately 103% of the Company's estimated full capacity of approximately $30 million per year. This production output helped reduce the backlog of orders to approximately $4.4 million as of January 1, 2025 from approximately $9.4 million as of January 1, 2024. The Company believes that the current backlog reflects strong demand as distributors work to replenish their buffer stocks and as end-users place orders in advance of peak calving season during the first quarter.